

Revision: HCFA-PM (MB)

State/Territory: LOUISIANA

Citation

42 CFR 456.703

Sections 1902(a), 1902(oo), and 1927 of the Act

Section 1004 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act

Formatted: Right: 0.38"

Formatted: Font: Not Bold

Drug Utilization Review Requirements to Comply with the SUPPORT for Patients and Communities Act

Formatted: Normal, Right: 0.38", No bullets or numbering

Formatted: Font: Not Bold

1. Claims Review Limitations

Formatted: Indent: Left: 0.5", Right: 0.38", No bullets or numbering

The State has opioid-related prospective point of sale (POS) safety edits and retrospective reviews in place to address:

- a. Duplicate fill and early fill alerts;
- b. Quantity limits;
- c. Morphine milligram equivalent (MME) limits; and
- d. Therapeutic duplication edits for:
 - i. Opioids/benzodiazepines
 - ii. Short-acting opioids/short-acting opioids
 - iii. Long-acting opioids/long-acting opioids

Formatted: Indent: Left: 0", Right: 0.38"

Formatted: Right: 0.38", Line spacing: Exactly 10 pt

Formatted: Indent: Left: 0.25", Right: 0.38"

Formatted: Indent: Left: 0.5", Right: 0.38"

Formatted: Indent: Left: 1", Hanging: 0.25", Right: 0.38"

The State has the following annual retrospective utilization reviews for opioid safety:

- a. Concurrent opioid with benzodiazepines;
- b. Concurrent opioid with sleep agents;
- c. Concurrent opioid with antipsychotic agents; and
- d. Fentanyl transdermal, focus on Centers for Disease Control and Prevention (CDC) Guideline.

Formatted: Right: 0.38", Line spacing: Exactly 10 pt

Formatted: Indent: Left: 0.25", Right: 0.38"

Formatted: Indent: Left: 0.5", Right: 0.38"

2. Program to Monitor Antipsychotic Medications by Children

Formatted: Right: 0.38"

Formatted: Indent: Left: 0", Right: 0.38"

Formatted: Right: 0.38", Line spacing: Exactly 10 pt

Formatted: Indent: Left: 0.25", Right: 0.38"

The State has therapeutic duplication edits for oral/oral antipsychotic agents and injectable/injectable antipsychotic agents. Clinical authorization is required for antipsychotic medications prescribed for all children 0-5 years old. Antipsychotic medications have quantity limits and/or maximum doses and require a diagnosis code for all recipients. Pharmacy claims that exceed these limits will deny at POS. Overrides are addressed by the pharmacist after consultation with the prescriber or through the prior authorization process, depending on the edit.

The State performs annual retrospective utilization reviews for concurrent use of antipsychotic agents.

Formatted: Right: 0.38"

Formatted: Indent: Left: 0.25", Right: 0.38"

Formatted: Right: 0.38"

3. Fraud and Abuse Identification

Recipient profiles are reviewed based on pre-determined criteria. If potential misuse or over-utilization is identified, the recipient will be referred for pharmacy and/or prescriber lock-in.

4. Medicaid Managed Care Organizations Requirements

Effective October 1, 2019, the Louisiana MCO contracts were revised to comply with requirements of Section 1004 of the SUPPORT for Patients and Communities Act.

- ← Formatted: Indent: Left: 0", Right: 0.32"
- ← Formatted: Right: 0.32"
- ← Formatted: Indent: Left: 0", Right: 0.32"
- ← Formatted: Right: 0.32"